Stocks from the healthcare sector were not popular with investors on Tuesday.
The securities of the laboratory supplier Sartorius ultimately fell by 2.85 percent to 335.30 euros via XETRA at the end of the DAX. They slipped back below the 200-day line, which is receiving great attention on the market as an indicator of the longer-term trend.
Bayer shares fell 2.16 percent to 30.08 euros at the close of trading. At times it even fell to its lowest level since the end of 2005. The US court proceedings surrounding the weed killer glyphosate and concerns about possible additional provisions had a latent impact on the price. A trader also pointed out that the US investment house Wolfe Research had lowered the shares from “Outperform” to “Peer Perform”.
The shares of Merck KGaA lost 1.4 percent to 151.55 euros. As on the previous day, the chemical and pharmaceutical company’s stocks missed the jump back above the 200-day line. The line has represented stubborn resistance for the price since spring of last year.
/bek/jha/
Selected leverage products on Bayer
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Bayer
The leverage must be between 2 and 20
Advertising